Why NaV1.8 Is the Defining Target in Peripheral Neuropathic Pain

The NaV1.8 voltage-gated sodium channel — encoded by the SCN10A gene — is preferentially expressed in peripheral sensory neurons and plays a central role in generating and sustaining the abnormal electrical activity that underlies neuropathic pain. Unlike the non-selective sodium channel blockers that dominated pain pharmacology for decades, a compound that inhibits NaV1.8 selectively can attenuate peripheral pain signalling while leaving cardiac channels (NaV1.5), skeletal muscle channels (NaV1.4), and central nervous system channels (NaV1.1, NaV1.2) essentially untouched.

This selectivity profile is clinically significant for diabetic peripheral neuropathy (DPN), where chronic hyperglycaemia damages small-fibre sensory neurons and drives the upregulation and sensitisation of peripheral sodium channels — particularly NaV1.8. Patients with DPN experience burning, shooting, or electric-shock pain that current standard-of-care agents (gabapentinoids, SNRIs, tricyclic antidepressants) address only partially and often with dose-limiting central side effects including sedation, cognitive impairment, and, in the case of opioids, addiction risk.

Patent filings from Vertex Pharmaceuticals — retrievable via PatSnap’s global patent database — describe sulfonamide compounds of Formula (I) that inhibit NaV1.8 and are indicated for the treatment of pain, including nociceptive pain, neuropathic pain, nociceptive pain combined with neuropathic pain, visceral pain, inflammatory pain, and migraine. The breadth of this claim language, visible in patents such as US20220185798A1 and US11780839B2, signals that Vertex has deliberately constructed a therapeutic franchise around the NaV1.8 mechanism rather than a single indication.

Suzetrigine’s Patent Portfolio: Chemistry, Crystalline Forms, and Method Claims

Vertex Pharmaceuticals has constructed a multi-layered patent estate around suzetrigine that spans at least six distinct claim categories, each designed to provide overlapping protection as the asset advances through later-stage clinical development and into commercial use.

Compound and composition claims

The foundational layer of Vertex’s portfolio covers the sulfonamide chemical entities themselves. Multiple US and PCT applications — including US20230339964A1, US20230286960A1, US20230286961A1, US20230357261A1, and the granted patent US12024504B2 (issued 2 July 2024) — describe sulfonamide compounds of Formula (I), their N-oxides, and pharmaceutically acceptable salts as NaV1.8 inhibitors for the treatment of pain. A further granted patent, US12060346B2 (issued 13 August 2024), reinforces the compound protection. Crystalline form claims — filed in US20230145219A1 and US20240002352A1 — extend protection to specific solid-state forms, which is a standard strategy to prevent generic substitution even after the base compound patent expires.

Method-of-treatment claims

Layered above the composition claims is a dense set of method-of-treatment filings. Patents such as US20230098736A1, US20230098718A1, US20230098717A1, WO2023009510A1, and multiple 2024 continuations (US20240238273A1, US20240269124A1, US20240342112A1, US20240342113A1, US20240358693A1) cover methods for treating pain using NaV1.8 inhibitors such as suzetrigine. This family of applications, which spans both US national phase and PCT international filings, ensures that the method of use — not just the molecule — is protected across major jurisdictions recognised by WIPO.

Combination therapy claims

A strategically important cluster of filings covers suzetrigine in combination with one or more additional pain medications. US20230321041A1, US20240156795A1, and WO2023009507A1 describe methods for treating pain using suzetrigine in combination regimens. These claims are particularly relevant for the DPN setting, where patients are frequently on polypharmacy regimens and where a combination approach — for example, suzetrigine plus a gabapentinoid or SNRI — could offer additive or synergistic efficacy while allowing dose reduction of the partner agent.

The DPN Expansion: Comorbid Populations and Special Patient Groups

Diabetic peripheral neuropathy is not a clean, isolated indication — it arrives in patients who are already managing type 2 diabetes, hypertension, chronic kidney disease, and cardiovascular disease. Vertex’s patent filings reflect a sophisticated awareness of this clinical reality, with a dedicated cluster of applications addressing suzetrigine’s use in patients with comorbid conditions and compromised organ function.

The comorbid condition cluster is particularly extensive. Eight PCT and US applications — including WO2024163705A1, WO2024163706A1, WO2024163707A1, WO2024163708A1, US20240261265A1, US20240261266A1, US20240261267A1, and US20240252528A1/US20240252529A1 — all published in mid-2024 and describe methods for treating pain in patients with comorbid conditions using a NaV1.8 inhibitor such as suzetrigine. The simultaneous PCT and US prosecution of this cluster is consistent with Vertex preparing for a global regulatory submission in an indication where the target patient population is, by definition, medically complex.

The renal function filings are especially significant in the DPN context. Diabetic nephropathy and diabetic peripheral neuropathy share the same underlying aetiology — chronic hyperglycaemia — and frequently co-occur. Gabapentin and pregabalin, the most widely prescribed agents for DPN pain, require dose adjustment in renal impairment and accumulate in end-stage kidney disease. A NaV1.8 inhibitor that is pharmacokinetically characterised and safe in renally impaired patients would address a substantial unmet need identified by organisations such as WHO in global diabetes burden analyses.

“Vertex has filed dedicated patent applications for suzetrigine in patients with compromised renal and hepatic function — precisely the comorbid populations that define the real-world diabetic peripheral neuropathy patient.”

From an IP strategy perspective, these special-population method claims serve a dual purpose. First, they protect Vertex’s clinical investment in characterising suzetrigine’s pharmacokinetics and safety in complex patients — data that generics cannot easily replicate without conducting their own studies. Second, they create a regulatory moat: a competitor seeking to market a generic version of suzetrigine for DPN in renally impaired patients would need to design around these method claims or wait for their expiry.

Competitive Dynamics in the NaV1.8 Inhibitor Space

Vertex’s suzetrigine portfolio, as revealed by PatSnap’s patent database, dominates the NaV1.8 inhibitor landscape in terms of publication volume and claim breadth. The search results across more than 50 patent publications are overwhelmingly assigned to Vertex Pharmaceuticals, with no competing assignee appearing in the NaV1.8-specific sulfonamide inhibitor space at comparable scale.

This concentration is strategically significant. In the voltage-gated sodium channel field more broadly, several companies have pursued NaV1.7 inhibitors for pain — a programme that has historically disappointed in clinical trials, partly because NaV1.7 loss-of-function mutations in humans cause congenital insensitivity to pain but the pharmacological inhibition of NaV1.7 in adults has not replicated this effect. NaV1.8’s clinical validation — suzetrigine’s FDA approval in January 2025 for acute pain — changes the competitive calculus. As noted by Nature in its coverage of ion channel pharmacology, validated human genetics combined with selective pharmacology is the most predictive combination for clinical success in pain drug development.

The combination therapy patent cluster (US20230321041A1, US20240156795A1, WO2023009507A1) also carries competitive implications. By patenting suzetrigine’s use alongside “one or more additional pain medications,” Vertex is staking a claim on the clinical practice of combination analgesia in DPN — a practice that is likely to become standard given the multimechanistic nature of diabetic neuropathic pain. Any competitor developing a second-generation NaV1.8 inhibitor would need to navigate these combination claims if they wish to position their molecule as an add-on therapy. Standards for patent claim construction in this area are guided by guidelines from the USPTO.

What the IP Signals Mean for the Phase III DPN Readout

The patent filing timeline provides a reliable proxy for Vertex’s internal clinical confidence in suzetrigine for diabetic peripheral neuropathy. The acceleration from 4 publications in 2022 to 26 in 2023 and 28 in 2024 — with the comorbid condition and special population clusters appearing predominantly in 2024 — is consistent with a programme that has generated sufficiently compelling Phase II DPN data to justify intensive IP prosecution ahead of Phase III initiation and potential regulatory submission.

Several signals in the patent record are worth highlighting for R&D intelligence purposes:

• Timing of crystalline form claims: US20230145219A1 (May 2023) and US20240002352A1 (January 2024) cover crystalline forms of the NaV1.8 inhibitor. Crystalline form filings typically accompany or immediately precede the selection of a commercial drug substance form — suggesting that Vertex had locked down its manufacturing process by early 2024.
• Breadth of pain indication language: Claims covering nociceptive pain, neuropathic pain, visceral pain, inflammatory pain, and migraine in a single patent family (US20220185798A1, US11780839B2) indicate that Vertex is preserving optionality across multiple future indications beyond DPN.
• Simultaneous PCT and US prosecution: The parallel filing of PCT applications (WO2024163703A1 through WO2024163708A1) alongside their US counterparts signals preparation for global regulatory filings — consistent with a Phase III programme designed to support submissions to the EMA and other major health authorities in parallel with the FDA.
• Renal and hepatic function claims: The dedicated organ-function filings (US20240082239A1, US20240082238A1, US20240139163A1, US20240139164A1) are consistent with the FDA’s standard requirement for pharmacokinetic studies in special populations as part of a new drug application — suggesting these studies are either complete or well advanced.

For drug discovery professionals and IP strategists monitoring this space, the PatSnap patent database provides claim-level granularity on each of these filings, enabling precise freedom-to-operate analysis, claim mapping, and competitive benchmarking. The PatSnap pharmaceutical intelligence platform aggregates patent, clinical trial, regulatory, and literature data into a single searchable environment — allowing teams to move from a patent publication number to a full competitive landscape in minutes.